Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,272 total articles

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Quantum BioPharma Ltd., listed on NASDAQ as QNTM, announced its innovative drug candidate Lucid-MS, designed to directly target and repair the myelin sheath damaged in multiple sclerosis (MS). This novel approach differs fundamentally from existing therapies that only slow disease progression. Lucid-MS is preparing to enter phase 2 clinical trials,…

Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical Inc. announced that a leading academic health system in Pennsylvania has adopted its LIBERTY® Endovascular Robotic System, marking the company's expansion into a seventh U.S. state. This adoption strengthens Microbot's foothold in the Northeast, following other health systems in New York and Boston. The company is progressing with …

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

Silo Pharma announced positive stability data for SPC-15, their investigational intranasal treatment for PTSD, confirming its physical, chemical, and microbiological stability over nine months. This milestone supports the advancement of the FDA IND-enabling program and prepares the company for a first-in-human Phase 1 clinical trial, emphasizing ad…

LM Funding America Announces Strategic Expansion into High-Performance Computing and AI Infrastructure

LM Funding America Announces Strategic Expansion into High-Performance Computing and AI Infrastructure

LM Funding America, a Nasdaq-listed Bitcoin treasury and mining company, announced a strategic expansion into high-performance computing (HPC) and artificial intelligence (AI) infrastructure. Leveraging its 26 megawatts of wholly-owned low-cost power infrastructure across Oklahoma and Mississippi, the company has ordered initial AI GPU server hardw…

Alpha Cash Comes Home: North Carolina Approval Takes Seven-State Footprint Past 3 Million Unbanked Households

Alpha Cash Comes Home: North Carolina Approval Takes Seven-State Footprint Past 3 Million Unbanked Households

Alpha Modus Holdings, Inc. announced that its financial services subsidiary, Alpha Modus Financial Services, LLC, received regulatory approval to operate in North Carolina as an authorized delegate for Barri Money Services. This approval allows Alpha Cash to offer check deposit and remittance services via kiosks and a mobile app to North Carolina r…

Safe Pro Awarded New $1.3 Million U.S. Army Subcontract to Integrate Real-Time AI Landmine Detection into Unmanned Ground Vehicles

Safe Pro Awarded New $1.3 Million U.S. Army Subcontract to Integrate Real-Time AI Landmine Detection into Unmanned Ground Vehicles

Safe Pro Group Inc., a Nasdaq-listed AI defense technology company, announced it has secured a $1.3 million subcontract from the U.S. Army to integrate its AI-based real-time explosive threat detection technology into autonomous unmanned ground vehicles (UGVs). This contract, awarded through a major U.S. defense prime contractor, will enable Safe P…

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

Alps Group Inc, a Nasdaq-listed biotechnology platform headquartered in Malaysia, announced its entry into patient-derived organoid technology through a collaboration with Dr. Kong Wai Mun. The new program aims to develop Malaysia's first clinically validated PDO platform to advance personalized cancer care and preclinical drug screening. This init…

Exyn Technologies Rebrands Range Subsidiary as Exyn Defense

Exyn Technologies Rebrands Range Subsidiary as Exyn Defense

Exyn Technologies has rebranded its defense-focused subsidiary, Range, as Exyn Defense, Inc. This move aligns its government and defense operations under the Exyn brand to better target autonomous autonomy and mapping software solutions for GPS-denied and high-risk environments. Exyn Defense aims to leverage the company's proven ExynAI technology t…

One Stop Systems Set to Join US Small-Cap Russell 2000® Index

One Stop Systems Set to Join US Small-Cap Russell 2000® Index

One Stop Systems, Inc., a leader in rugged high-performance compute solutions for AI and edge applications, announced its anticipated inclusion in the US small-cap Russell 2000® Index effective June 29, 2026. This milestone recognizes the company's growth strategy execution and is expected to enhance its access to passive and active institutional i…

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics has announced the appointment of Corsee Sanders, Ph.D., a seasoned biopharma executive with leadership experience at Genentech/Roche and Celgene, to its Board of Directors. Dr. Sanders' expertise is expected to support Calidi's clinical advancement of its RedTail platform and lead candidate CLD-401 targeting multiple cancers.…

Park Ha Biological Technology Co., Ltd. announces strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) to build an AI-driven ecosystem for the beauty industry.

Park Ha Biological Technology Co., Ltd. announces strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) to build an AI-driven ecosystem for the beauty industry.

Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) has formed a strategic partnership with Hong Kong-listed Cloud Factory Technology Holdings Limited to co-develop an AI-driven ecosystem aimed at transforming the beauty industry through improved operational efficiency, digital tools, and smart resource utilization. The collaboration leverages C…

ZenaTech Expands Drone as a Service Platform with 24th Acquisition, Adding Green Earth Powerwashing Franchise Network

ZenaTech Expands Drone as a Service Platform with 24th Acquisition, Adding Green Earth Powerwashing Franchise Network

ZenaTech, a Nasdaq-listed technology company specializing in AI-powered drones and Drone as a Service (DaaS), has acquired Green Earth Powerwashing LLC, a Florida-based franchise providing exterior cleaning and property maintenance services. This 24th acquisition strengthens ZenaTech's footprint in Florida and integrates drone-powered cleaning into…

From the pitch to the airport: Cristiano Ronaldo and Vini Jr. chosen as Brazil’s dream travel buddies, reveals KAYAK

From the pitch to the airport: Cristiano Ronaldo and Vini Jr. chosen as Brazil’s dream travel buddies, reveals KAYAK

KAYAK, a travel search engine under Booking Holdings, surveyed 2,000 Brazilian travelers to identify which football players they most want to travel with, with Cristiano Ronaldo leading at 60%. The Northeast region of Brazil, particularly Bahia, was the preferred destination. The survey insights aim to influence travel plans and promote destination…

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, announced it will present Phase 1a clinical data of its novel dual-targeting biologic TH103 at the American Society of Retina Specialists 2026 Annual Meeting. The company is actively enrolling patients in its Phase 1b/2 trial for TH103 targeting neovascular Age-related Macular Degene…

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics announced positive feedback from its Type C meeting with the FDA, securing agreement on the primary endpoint and regulatory path for belapectin's Phase 3 trial targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The Phase 3 protocol filing is planned for Q3 2026, with strategic …

ASP Isotopes Inc. Announces that a Subsidiary of Renergen Limited Has Entered into its First Take-or-Pay Contract for the Supply of Contained Helium to be Produced at the Virginia Gas Project in South Africa

ASP Isotopes Inc. Announces that a Subsidiary of Renergen Limited Has Entered into its First Take-or-Pay Contract for the Supply of Contained Helium to be Produced at the Virginia Gas Project in South Africa

ASP Isotopes Inc. announced that its subsidiary Renergen Limited's Tetra4 has entered into its first five-year take-or-pay contract to supply contained helium to an Asian industrial gases company from the Virginia Gas Project in South Africa. Phase 1 commercial operations remain targeted for Q3 2026, with helium sales priced above $600/MCF. Phase 2…

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

IMUNON announced that the independent Data Monitoring Committee has recommended continuation of its pivotal Phase 3 OVATION 3 study evaluating IMNN-001 in advanced ovarian cancer patients without any modifications. The trial remains on track to enroll approximately 80 patients by Q1 2027. The decision reflects the strong safety and efficacy profile…

Veea Inc. and TROLLEE Holdings Ltd. Extend Strategic Partnership to Deliver a Highly Advanced AI-Powered Autonomous Retail Ecosystem

Veea Inc. and TROLLEE Holdings Ltd. Extend Strategic Partnership to Deliver a Highly Advanced AI-Powered Autonomous Retail Ecosystem

Veea Inc. (NASDAQ: VEEA) and TROLLEE Holdings Limited have extended their strategic partnership to develop an advanced AI-driven autonomous retail ecosystem. The collaboration integrates Veea's edge-AI infrastructure with TROLLEE's smart shopping carts and retail robotics to enable fully autonomous stores that enhance inventory management, security…